Clinical Trial Update: A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study (LADOGA) evaluating durvalumab with oleclumab after chemoradiation in locally advanced unresectable non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Oleclumab (oleclumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING